IN2013MU02145A - - Google Patents

Download PDF

Info

Publication number
IN2013MU02145A
IN2013MU02145A IN2145MU2013A IN2013MU02145A IN 2013MU02145 A IN2013MU02145 A IN 2013MU02145A IN 2145MU2013 A IN2145MU2013 A IN 2145MU2013A IN 2013MU02145 A IN2013MU02145 A IN 2013MU02145A
Authority
IN
India
Prior art keywords
monoclonal antibody
purification
provides
desired monoclonal
purity
Prior art date
Application number
Other languages
English (en)
Inventor
Sanjay Bandyopadhyay
Sanjeev Kumar Mendiratta
Avanish Kumar Singh
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51655799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2013MU02145(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to TW103121726A priority Critical patent/TWI596107B/zh
Priority to ARP140102380A priority patent/AR096713A1/es
Priority to CN201480031532.XA priority patent/CN105263947A/zh
Priority to PCT/IN2014/000421 priority patent/WO2014207763A1/en
Priority to BR112015031196A priority patent/BR112015031196A2/pt
Priority to EA201592192A priority patent/EA201592192A1/ru
Priority to US14/895,432 priority patent/US9708365B2/en
Priority to HK16105366.7A priority patent/HK1217344A1/zh
Priority to IN2145MU2013 priority patent/IN2013MU02145A/en
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to SG11201509502XA priority patent/SG11201509502XA/en
Priority to AU2014300486A priority patent/AU2014300486B2/en
Priority to EP14777867.4A priority patent/EP3013849B1/en
Priority to CA2911874A priority patent/CA2911874A1/en
Priority to KR1020157035759A priority patent/KR101683415B1/ko
Priority to MX2015016586A priority patent/MX350610B/es
Priority to NZ714079A priority patent/NZ714079A/en
Priority to JP2015563045A priority patent/JP6039828B2/ja
Publication of IN2013MU02145A publication Critical patent/IN2013MU02145A/en
Priority to ZA2015/08258A priority patent/ZA201508258B/en
Priority to IL242649A priority patent/IL242649A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
IN2145MU2013 2013-06-25 2014-06-25 IN2013MU02145A (https=)

Priority Applications (19)

Application Number Priority Date Filing Date Title
TW103121726A TWI596107B (zh) 2013-06-25 2014-06-24 單株抗體之新穎純化方法
ARP140102380A AR096713A1 (es) 2013-06-25 2014-06-24 Proceso de purificación para anticuerpos monoclonales
JP2015563045A JP6039828B2 (ja) 2013-06-25 2014-06-25 モノクローナル抗体の精製方法
AU2014300486A AU2014300486B2 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
BR112015031196A BR112015031196A2 (pt) 2013-06-25 2014-06-25 “processo de purificação de anticorpo monoclonal”
EA201592192A EA201592192A1 (ru) 2013-06-25 2014-06-25 Способ очистки моноклональных антител
US14/895,432 US9708365B2 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
HK16105366.7A HK1217344A1 (zh) 2013-06-25 2014-06-25 单克隆抗体的纯化工序
IN2145MU2013 IN2013MU02145A (https=) 2013-06-25 2014-06-25
CN201480031532.XA CN105263947A (zh) 2013-06-25 2014-06-25 单克隆抗体的纯化工艺
SG11201509502XA SG11201509502XA (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
PCT/IN2014/000421 WO2014207763A1 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
EP14777867.4A EP3013849B1 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
CA2911874A CA2911874A1 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
KR1020157035759A KR101683415B1 (ko) 2013-06-25 2014-06-25 단일클론항체에 대한 정제 방법
MX2015016586A MX350610B (es) 2013-06-25 2014-06-25 Proceso para la purificacion de anticuerpos monoclonales.
NZ714079A NZ714079A (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
ZA2015/08258A ZA201508258B (en) 2013-06-25 2015-11-09 Purification process for monoclonal antibodies
IL242649A IL242649A (en) 2013-06-25 2015-11-18 Purification process of monoclonal antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2145MU2013 IN2013MU02145A (https=) 2013-06-25 2014-06-25

Publications (1)

Publication Number Publication Date
IN2013MU02145A true IN2013MU02145A (https=) 2015-06-05

Family

ID=51655799

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2145MU2013 IN2013MU02145A (https=) 2013-06-25 2014-06-25

Country Status (19)

Country Link
US (1) US9708365B2 (https=)
EP (1) EP3013849B1 (https=)
JP (1) JP6039828B2 (https=)
KR (1) KR101683415B1 (https=)
CN (1) CN105263947A (https=)
AR (1) AR096713A1 (https=)
AU (1) AU2014300486B2 (https=)
BR (1) BR112015031196A2 (https=)
CA (1) CA2911874A1 (https=)
EA (1) EA201592192A1 (https=)
HK (1) HK1217344A1 (https=)
IL (1) IL242649A (https=)
IN (1) IN2013MU02145A (https=)
MX (1) MX350610B (https=)
NZ (1) NZ714079A (https=)
SG (1) SG11201509502XA (https=)
TW (1) TWI596107B (https=)
WO (1) WO2014207763A1 (https=)
ZA (1) ZA201508258B (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH088818Y2 (ja) 1989-12-21 1996-03-13 株式会社イナックス タイル用捺印装置
TWI398554B (zh) * 2010-07-29 2013-06-11 Zhen Ding Technology Co Ltd 電鍍裝置
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
EP3057616B1 (en) 2013-10-16 2020-03-11 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
WO2016118707A1 (en) * 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
WO2016149088A1 (en) * 2015-03-13 2016-09-22 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
EP3337818B1 (en) * 2015-08-21 2026-03-18 F. Hoffmann-La Roche AG Affinity chromatography purification with low conductivity wash buffer
SI3337812T1 (sl) * 2015-08-21 2021-08-31 F. Hoffmann-La Roche Ag Postopek za zmanjševanje beljakovin gostiteljske celice v afinitetni kromatografiji
HRP20211737T1 (hr) 2015-08-21 2022-02-18 F. Hoffmann - La Roche Ag Postupak za smanjenje proteina stanice domaćina u afinitetnoj kromatografiji
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
US11020686B2 (en) 2016-08-16 2021-06-01 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
JP7102401B2 (ja) 2016-10-25 2022-07-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド クロマトグラフィーデータ解析のための方法およびシステム
US12162938B2 (en) 2016-10-28 2024-12-10 Merck Sharp & Dohme Llc Purification process for removal of tyrosine sulfation antibody variants; purified compositions
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CR20190291A (es) 2016-12-23 2019-11-05 Serum Institute Of India Pvt Ltd Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamiferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos
AR111761A1 (es) * 2017-05-16 2019-08-14 Cj Healthcare Corp Un método para purificar un anticuerpo o un fragmento de anticuerpo de este usando cromatografía de afinidad
EP3431168A1 (en) * 2017-07-19 2019-01-23 Bayer Aktiengesellschaft Élimination de médicament non lié après couplage conjugué anticorps-médicament
CA3073935A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals, Inc. Methods of reducing particle formation and compositions formed thereby
CN108101987A (zh) * 2017-11-17 2018-06-01 安徽未名生物医药有限公司 一种重组抗TNF-α全人源单克隆抗体的纯化方法
CN110128538B (zh) * 2018-02-09 2022-08-26 鲁南制药集团股份有限公司 一种纯化抗cd20人鼠嵌合单克隆抗体的方法
WO2019183334A1 (en) 2018-03-21 2019-09-26 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbents, devices and methods
JP7840636B2 (ja) * 2018-04-02 2026-04-06 アムジェン インコーポレイテッド エレヌマブ組成物及びその使用
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
WO2020016417A1 (en) * 2018-07-19 2020-01-23 Ichnos Sciences S.A. Liquid antibody formulation
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CN111072773A (zh) * 2018-10-19 2020-04-28 菲鹏生物股份有限公司 抗体的纯化方法、抗体和应用
EP3643322A1 (en) * 2018-10-26 2020-04-29 Mabion SA Low aggregate anti cd20 ligand formulation
WO2020084503A1 (en) 2018-10-26 2020-04-30 Cadila Healthcare Limited A composition comprising antibody with reduced level of basic variants thereof
CN109320611B (zh) * 2018-10-31 2022-06-03 鼎康(武汉)生物医药有限公司 一种人鼠嵌合单克隆抗体生物类似药的纯化方法
CN111153993B (zh) * 2018-11-07 2024-06-28 正大天晴药业集团南京顺欣制药有限公司 抗TNF-α单克隆抗体的制备方法
CN109336969B (zh) * 2018-11-09 2021-02-12 杭州奕安济世生物药业有限公司 一种抗体的纯化方法
CN111269316B (zh) * 2018-12-04 2024-06-28 正大天晴药业集团南京顺欣制药有限公司 抗her2单克隆抗体的纯化方法
WO2020153390A1 (ja) * 2019-01-23 2020-07-30 第一三共株式会社 活性炭材料を使用する工程を含む抗体精製方法
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
EP4061825A1 (en) 2019-11-22 2022-09-28 MorphoSys AG Method to increase antibody yield during ion exchange chromatography
CN114929725A (zh) * 2020-01-08 2022-08-19 信达生物制药(苏州)有限公司 阿达木单抗纯化方法及其稳定组合物
KR102154952B1 (ko) * 2020-02-21 2020-09-10 프레스티지바이오로직스 주식회사 아달리무맙의 Non-Protein A 정제방법
WO2022245306A1 (en) * 2021-05-20 2022-11-24 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Protein purification by affinity chromatography
IL310409B2 (en) 2021-07-27 2026-04-01 Ariel Scient Innovations Ltd High-volume antibody purification
CN114133446A (zh) * 2021-12-31 2022-03-04 方坦思(上海)生物医药有限公司 单克隆抗体的纯化方法
CN115491328A (zh) * 2022-08-31 2022-12-20 深圳市卫光生物制品股份有限公司 一种大肠杆菌表达蛋白及其表达纯化方法
EP4335869A1 (en) 2022-09-07 2024-03-13 Bio T Biyoteknoloji Cozumleri Ve Uretim Anonim Resin and chromatography column that purifies antibodies with protease resistant small peptides
CN118725127B (zh) * 2024-07-11 2025-11-28 信立泰(苏州)药业有限公司 一种抗pcsk9单克隆抗体的分离纯化方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DK1308455T3 (da) 1998-05-06 2006-07-31 Genentech Inc Sammensætning omfattende anti-HER2-antistoffer
NZ507557A (en) 1998-05-06 2003-10-31 Genentech Inc Protein purification by ion exchange chromatography
EP1500661A1 (en) * 1998-06-01 2005-01-26 Genetech, Inc. Separation of protein monomers from aggregates by use of ion-exchange chromatography
JPWO2004087761A1 (ja) 2003-03-31 2006-07-27 麒麟麦酒株式会社 ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
SE0400501D0 (sv) 2004-02-27 2004-02-27 Amersham Biosciences Ab Antibody purification
EP1869065B1 (en) * 2005-03-11 2020-05-06 Wyeth LLC A method of weak partitioning chromatography
ZA200710330B (en) 2005-06-17 2009-12-30 Wyeth Corp Methods of purifying FC region containing proteins
WO2007109163A2 (en) 2006-03-16 2007-09-27 Amgen Inc Wash buffer and method of using
CN102887955A (zh) 2006-04-05 2013-01-23 艾博特生物技术有限公司 抗体纯化
CN101511387A (zh) 2006-09-08 2009-08-19 惠氏公司 使用亲和色谱法纯化蛋白质的精氨酸洗涤液
JP2011500086A (ja) 2007-10-22 2011-01-06 シェーリング コーポレイション 完全ヒト抗ｖｅｇｆ抗体および使用方法
US20110166332A1 (en) 2008-09-12 2011-07-07 Ge Healthcare Bio-Sciences Ab Enhanced antibody aggregate removal with capto adhere in the presence of protein-excluded zwitterions
US20100069617A1 (en) 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal by mixed mode chromatography on hydrophobic interaction media in the presence of protein-excluded zwitterions
NZ592095A (en) 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
ES2813398T3 (es) 2009-10-20 2021-03-23 Abbvie Inc Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
EP2519536A4 (en) * 2009-12-29 2013-06-05 Reddys Lab Ltd Dr PROTEIN PURIFICATION BY ION EXCHANGE
SG182553A1 (en) 2010-01-22 2012-08-30 Boehringer Ingelheim Int Chromatographic method for purifying fc-containing proteins
CN102179237A (zh) * 2010-04-26 2011-09-14 无锡加莱克色谱科技有限公司 一种用于分离、提纯单克隆抗体和抗体球蛋白的亲和色谱填料及其制备方法
EP2627425A4 (en) * 2010-10-11 2014-11-05 Abbvie Inc METHODS OF PURIFYING PROTEINS
JP2013544524A (ja) * 2010-12-06 2013-12-19 ターポン バイオシステムズ，インコーポレイテッド 生物学的生成物の連続プロセス法
WO2012125735A1 (en) 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
US20140128577A1 (en) * 2011-06-24 2014-05-08 Dr. Reddy's Laboratories Limited Purification of chimeric protein
EP2773439A4 (en) * 2011-10-31 2015-07-01 Merck Sharp & Dohme CHROMATOGRAPHY METHOD FOR RESOLVING HETEROGENIC ANTIBODY AGGREGATES
WO2013075740A1 (en) 2011-11-23 2013-05-30 Sanofi Antibody purification method
SI3395423T1 (sl) * 2013-03-14 2023-12-29 Amgen Inc. Odstranjevanje izluženega liganda za afinitetno čiščenje
HK1222871A1 (zh) * 2013-05-13 2017-07-14 Medimmune, Llc 具有最小单体分离的重组多克隆抗体多聚体的分离
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法

Also Published As

Publication number Publication date
EA201592192A1 (ru) 2016-07-29
EP3013849B1 (en) 2017-09-13
BR112015031196A2 (pt) 2017-07-25
KR20160003311A (ko) 2016-01-08
AU2014300486A1 (en) 2015-11-26
CN105263947A (zh) 2016-01-20
TWI596107B (zh) 2017-08-21
HK1217344A1 (zh) 2017-01-06
MX350610B (es) 2017-09-11
AU2014300486B2 (en) 2016-06-30
KR101683415B1 (ko) 2016-12-06
SG11201509502XA (en) 2015-12-30
JP2016525500A (ja) 2016-08-25
TW201512217A (zh) 2015-04-01
EP3013849A1 (en) 2016-05-04
ZA201508258B (en) 2017-03-29
IL242649A (en) 2016-03-31
US20160115195A1 (en) 2016-04-28
AR096713A1 (es) 2016-01-27
WO2014207763A1 (en) 2014-12-31
JP6039828B2 (ja) 2016-12-07
MX2015016586A (es) 2016-03-16
NZ714079A (en) 2017-05-26
CA2911874A1 (en) 2014-12-31
US9708365B2 (en) 2017-07-18

Similar Documents

Publication Publication Date Title
IN2013MU02145A (https=)
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2015015482A (es) Proceso continuo de multiples etapas para purificar anticuerpos.
JO3772B1 (ar) صيغة جسم مضاد لـ cgrp
MX364908B (es) Purificación de proteínas usando amortiguador bis-tris.
HK1206755A1 (en) Low acidic species compositions and methods for producing and using the same
PH12022551228A1 (en) Trem2 antibodies and uses thereof
PH12019502298A1 (en) Monoclonal antibody to pd-l1
WO2018140887A8 (en) Method for reducing bioburden in chromatography
MX366112B (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
MX2016013416A (es) Nuevo proceso de purificacion de gonadotropina.
EA201400273A1 (ru) Способ снижения тромбоэмболического потенциала композиции, содержащей полученный из плазмы иммуноглобулин
MX2016000181A (es) Explicacion de la optimizacion de entrada de la cromatografia de intercambio ionico.
SG10201806643WA (en) Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
MY197993A (en) Method for protein purification
JOP20200106A1 (ar) جسم مضاد أحادي النسيلة مضاد لـ il-5r?
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
MX2015013182A (es) Purificacion analitica basada en la afinidad de compuestos bioterapeuticos para el control de bioprocesos.
MX369054B (es) Detección de moléculas de ácido nucleico.
EP4239329A3 (en) Method and apparatus
HK1216654A1 (zh) 使用離子交換色譜來控制高甘露糖糖型的水平的方法
MX2015012300A (es) Procedimiento para la preparacion de 4-amino-1-(1s,4r,5s)-2-fluoro -4,5-dihidroxi-3-hidroximetil-ciclopent-2-enil)-1h-pirimidin-2-on a.
WO2013009686A3 (en) Methods for purification of arylsulfatase a
MX2019011343A (es) Un procedimiento para la purificacion de fragmentos de anticuerpos recombinantes.
WO2015004686A3 (en) A process for purification of efavirenz and intermediates thereof using chromatographic methods